← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Children'S Cancer Therapy Develop/Inst
Beaverton, OR
$3,313,454
Total funding
3
Grants
Funding over time
peak $437.7K · FY2015–25$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,313,454 · 3
By mechanism
R01$3,173,454 · 2
R03$140,000 · 1
Investigators at Children'S Cancer Therapy Develop/Inst
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$354,563
R01 · FY2015 · CA
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$338,550
R01 · FY2018 · CA
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$337,941
R01 · FY2017 · CA
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$328,393
R01 · FY2019 · CA
Cytokine- and Satellite Cell-mediated Muscle Disease Promotion$322,447
R01 · FY2016 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$303,780
R01 · FY2025 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$303,780
R01 · FY2021 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$297,704
R01 · FY2023 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$297,704
R01 · FY2022 · CA
Clinical & Mechanistic underpinnings to reducing PAX:FOXO1 for alveolar rhabdomyosarcoma$288,592
R01 · FY2024 · CA
Pilot Project Investigating the PAX3-FOXO1 Protein in the Rare Disease Rhabdomyosarcoma$140,000
R03 · FY2023 · TR